A guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer
Guidelines usually wait for a drug to be licensed for a use before recommending it. For old drugs no one will license, guidelines should act directly on trial evidence.
Guideline bodies (NCCN, ESMO, NICE) do recommend off-label uses but often slowly and inconsistently for interventions without a sponsor to submit evidence. The proposal is a standing fast-track procedure in major guideline organisations, triggered automatically by publication of a registration-quality randomised trial of an off-patent drug, with a decision within six months, an explicit statement of the recommendation's reimbursement implications, and a mechanism for payers to adopt it in the absence of a label.
- No incentive to repurpose cheap drugs · Old, cheap drugs with anti-cancer signals never get the trials they need because no one profits from the result.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.
Pages like this
not linked directly; found by shared links- IdeaGuidelines list the open trials at every decision point, updated monthly
Shares ESMO Clinical Practice Guidelines & MCBS, NCCN Guidelines, European Society for Medical Oncology (ESMO), Knowledge reaches practice too slowly.
- IdeaOpen licences for publicly funded cancer guidelines
Shares NCCN Guidelines, European Society for Medical Oncology (ESMO), Knowledge reaches practice too slowly.
- IdeaMicro-learning pushed to community oncologists within 30 days of a practice change
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
- IdeaOffline decision support for generalists treating common cancers in low-resource settings
Shares NCCN Guidelines, American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
- IdeaGive negative trials plenary slots at the big cancer conferences
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
- IdeaLabel every biomarker claim with an evidence phase, like drugs
Shares ESMO Clinical Practice Guidelines & MCBS, NCCN Guidelines, Knowledge reaches practice too slowly.
- IdeaEnd the abstract-to-paper gap: require full results with any conference presentation
Shares European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), Knowledge reaches practice too slowly.
- IdeaLive guideline-concordance dashboards for every tumour board, generated from the record
Shares ESMO Clinical Practice Guidelines & MCBS, NCCN Guidelines, Knowledge reaches practice too slowly.